SABR to Oligoprogressive Lesions Delays Change in Systemic Therapy in ER+ Advanced Breast Cancer
Administration of stereotactic ablative body radiotherapy to oligoprogressive lesions delayed a change in systemic therapy in patients with estrogen receptor–positive/HER2-negative breast cancer enrolled to the prospective phase 2 AVATAR trial.
Source: onclive.com